Sorry, you need to enable JavaScript to visit this website.
Skip to main content

A BOLD way to treat VVC

A broad-spectrum* triterpenoid antifungal with fungicidal activity1

BREXAFEMME, a non-azole, works by inhibiting glucan synthase.1

  • Fungicidal activity kills Candida1*
  • Compromises fungal cell wall integrity1
  • The same mechanism as echinocandins, which have been established as first-line treatment for invasive Candida infections in the hospital setting3,4

Based on in vitro studies. Clinical significance is unknown.

BREXAFEMME demonstrated in vitro activity against all Candida species that cause VVC, including azole-resistant strains.1

Illustration of Candida albicans.

A truly unique MOA in the treatment of VVC

BREXAFEMME is the only FDA-approved treatment for vaginal yeast infections that is fungicidal.1

Active against all Candida species, with attributes suited to the vaginal environment*

THE ANTIFUNGAL ATTRIBUTES OF BREXAFEMME1

Clinical efficacy shown vs Candida albicans tick mark
In vitro activity vs non-albicans Candida tick mark
In vitro activity vs azole-resistant strains tick mark
Exceptional vaginal tissue penetration tick mark
Retains activity in low pH tick mark

Based on in vitro studies. Clinical significance is unknown.

In animal studies, BREXAFEMME exhibited exceptional vaginal tissue penetration after oral administration—reaching up to 9 times the plasma concentration.1

BREXAFEMME retained in vitro antifungal activity based on minimal inhibitory concentration values when tested at pH 4.5 (the normal vaginal pH).1

With broad-spectrum, fungicidal activity,
prescribe BREXAFEMME for your patients with VVC.

Indication

BREXAFEMME® is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC).

Important Safety Information

  • BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp
  • BREXAFEMME administration during pregnancy may cause fetal harm based on animal studies. Prior to initiating treatment, verify pregnancy status in females of reproductive potential and advise them to use effective contraception during treatment
  • When administering BREXAFEMME with strong CYP3A inhibitors, the dose of BREXAFEMME should be reduced to 150 mg twice a day for one day. Administration of BREXAFEMME with strong CYP3A inducers should be avoided
  • Most common adverse reactions observed in clinical trials (incidence ≥2%) were diarrhea, nausea, abdominal pain, dizziness, and vomiting

To report SUSPECTED ADVERSE REACTIONS, contact SCYNEXIS, Inc. at 1-888-982-SCYX (1-888-982-7299) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

To report SUSPECTED ADVERSE REACTIONS, contact SCYNEXIS, Inc. at 1-888-982-SCYX (1-888-982-7299) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information and Patient Information.

References: 1. BREXAFEMME. Prescribing Information. SCYNEXIS, Inc.; 2021. 2. Scynexis, Inc. Updated June 2, 2021. Accessed July 2, 2021. https://www.scynexis.com/news-media/press-releases/detail/240/scynexis-announces-fda-approval-of-brexafemme. 3. Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the management of candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infec Dis. 2016;62(4):e1–50. 4. Gintjee TJ, Donnelley MA, Thompson GR 3 rd . Aspiring antifungal: review of current antifungal pipeline developments. J Fungi (Basel). 2020:6(1):28 doi:10.3390/jof601028. 5. Data on file [1]. SCYNEXIS, Inc., Jersey City, NJ. 6. Data on file [2]. SCYNEXIS, Inc., Jersey City, NJ. 7. Data on file [3]. SCYNEXIS, Inc., Jersey City. NJ. 8. Data on file [4]. SCYNEXIS, Inc., Jersey City. NJ.

Important Safety Information

Indication

  • BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp
  • BREXAFEMME administration during pregnancy may cause fetal harm based on animal studies. Prior to initiating treatment, verify pregnancy status in females of reproductive potential and advise them to use effective contraception during treatment
  • When administering BREXAFEMME with strong CYP3A inhibitors, the dose of BREXAFEMME should be reduced to 150 mg twice a day for one day. Administration of BREXAFEMME with strong CYP3A inducers should be avoided
  • Most common adverse reactions observed in clinical trials (incidence ≥2%) were diarrhea, nausea, abdominal pain, dizziness, and vomiting

To report SUSPECTED ADVERSE REACTIONS, contact SCYNEXIS, Inc. at 1-888-982-SCYX (1-888-982-7299) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

To report SUSPECTED ADVERSE REACTIONS, contact SCYNEXIS, Inc. at 1-888-982-SCYX (1-888-982-7299) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information and Patient Information.

BREXAFEMME® is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC).